0001209191-20-052462.txt : 20200930 0001209191-20-052462.hdr.sgml : 20200930 20200930163844 ACCESSION NUMBER: 0001209191-20-052462 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200928 FILED AS OF DATE: 20200930 DATE AS OF CHANGE: 20200930 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nolan Sean P. CENTRAL INDEX KEY: 0001569926 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 201212665 MAIL ADDRESS: STREET 1: C/O INTERMUNE, INC. STREET 2: 3280 BAYSHORE BLVD. CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7318 MORTON STREET CITY: DALLAS STATE: TX ZIP: 75209 BUSINESS PHONE: 212.551.8702 MAIL ADDRESS: STREET 1: 7318 MORTON STREET CITY: DALLAS STATE: TX ZIP: 75209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-28 0 0001806310 Taysha Gene Therapies, Inc. TSHA 0001569926 Nolan Sean P. C/O TAYSHA GENE THERAPIES, INC. 2280 INWOOD ROAD DALLAS TX 75235 1 0 0 0 Common Stock 2020-09-28 4 C 0 1089500 A 1089500 I See Footnote Common Stock 2020-09-28 4 C 0 1601 A 1091101 I See Footnote Series A Preferred Stock 2020-09-28 4 C 0 1000000 0.00 D Common Stock 1089500 0 I See Footnote Series B Preferred Stock 2020-09-28 4 C 0 1470 0.00 D Common Stock 1601 0 I See Footnote Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date. The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of LLC, and is deemed to have sole voting and investment power with respect to the securities. /s/ Kamran Alam, Attorney-in-Fact 2020-09-30